Regeneron Pharmaceuticals (REGN)
(Real Time Quote from BATS)
$1,204.91 USD
+3.15 (0.26%)
Updated Aug 28, 2024 01:06 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Revenues: Net product sales
- 7,078.00
- 6,893.70
- 12,117.20
- 5,567.60
- 4,834.40
- Revenue - Line of Business (LOBR)
- Revenues: Collaboration
- 5,503.10
- 4,914.10
- 3,673.30
- 2,372.50
- 2,616.00
- Revenue - Line of Business (LOBR)
- Revenues: Other Revenue
- 536.10
- 365.10
- 281.20
- 557.00
- 413.40
- Revenue - Line of Business (LOBR)
- Revenues: Eylea (Aflibercept): Total
- 9,214.80
- 9,647.40
- 9,384.70
- 7,908.70
- 7,541.60
- Revenue - Line of Business (LOBR)
- Revenues: Dupixent (dupilumab): Total
- 11,588.10
- 8,681.20
- 6,198.30
- 4,044.80
- 2,315.60
- Revenue - Line of Business (LOBR)
- Revenues: Libtayo: Total
- 868.80
- 578.00
- 458.20
- 348.20
- 193.80
- Revenue - Line of Business (LOBR)
- Revenues: Praluent (alirocumab): Total
- 638.90
- 467.40
- 421.10
- 358.80
- 288.70
- Revenue - Line of Business (LOBR)
- Revenues: Kevzara (sarilumab): Total
- 385.90
- 358.00
- 338.00
- 269.90
- 206.70
- Revenue - Geographic (GEOR)
- Revenues: Eylea (Aflibercept): US
- 5,719.60
- 6,264.60
- 5,792.30
- 4,947.20
- 4,644.20
- Revenue - Geographic (GEOR)
- Revenues: Eylea (Aflibercept): ROW
- 3,495.20
- 3,382.80
- 3,592.40
- 2,961.50
- 2,897.40
- Revenue - Geographic (GEOR)
- Revenues: Dupixent (dupilumab): US
- 8,855.60
- 6,668.00
- 4,713.00
- 3,226.20
- 1,871.20
- Revenue - Geographic (GEOR)
- Revenues: Dupixent (dupilumab): ROW
- 2,732.50
- 2,013.20
- 1,485.30
- 818.60
- 444.40
- Revenue - Geographic (GEOR)
- Revenues: Libtayo: US
- 538.80
- 374.50
- 306.30
- 270.70
- 175.70
- Revenue - Geographic (GEOR)
- Revenues: Libtayo: ROW
- 330.00
- 203.50
- 151.90
- 77.50
- 18.10
- Revenue - Geographic (GEOR)
- Revenues: Praluent (alirocumab): US
- 182.40
- 130.00
- 170.00
- 186.00
- 126.00
- Revenue - Geographic (GEOR)
- Revenues: Praluent (alirocumab): ROW
- 456.50
- 337.40
- 251.10
- 172.80
- 162.70
- Revenue - Geographic (GEOR)
- Revenues: Kevzara (sarilumab): US
- 214.70
- 199.70
- 161.90
- 141.60
- 129.00
- Revenue - Geographic (GEOR)
- Revenues: Kevzara (sarilumab): ROW
- 171.20
- 158.30
- 176.10
- 128.30
- 77.70
- Revenue - Geographic (GEOR)
- Revenues: Evkeeza: US
- 77.00
- 48.00
- 18.40
- 0.00
- --